Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06739668 · ClinicalTrials.gov registry record · NA

Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

A NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06739668 is a NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06739668, a NA study of Cognitive Dysfunction and Post-Acute COVID-19 Syndrome, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.

Conditions Studied

Cognitive Dysfunction Post-Acute COVID-19 Syndrome

Interventions

  • DEVICE Sham Device
  • DEVICE Pascal device

Study Locations (1)

New York

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-12-19
Est. Completion 2025-12-01
Phase NA

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06739668

The ClinicalTrials.gov registry entry for NCT06739668 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (98% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Sham Device is the first listed.

NCT06739668 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06739668 about?

NCT06739668 is a clinical study titled "Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction". The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PAS...

What is the current status of trial NCT06739668?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2024-12-19. Estimated completion is 2025-12-01.

What conditions does trial NCT06739668 study?

This clinical trial studies the following conditions: Cognitive Dysfunction, Post-Acute COVID-19 Syndrome.

What interventions are being tested in trial NCT06739668?

The interventions under investigation include: Sham Device (DEVICE), Pascal device (DEVICE).

Who is sponsoring clinical trial NCT06739668?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06739668 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cognitive Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cognitive Dysfunction

All registered trials for this condition

Post-Acute COVID-19 Syndrome

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.